|
Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Suppliers list
|
| Company Name: |
Wuhan ChemFaces Biochemical Co., Ltd.
|
| Tel: |
18607101326 15172504745 |
| Email: |
aileen@chemfaces.com |
| Products Intro: |
Product Name:Yadanzigan
CAS:76588-87-9
Purity:>=98% Package:5mg ,10mg ,20mg ,50mg ,100mg; 200mg; 500mg,可根据客户需求定制 Remarks:2478/5mg
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847 13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Yadanzigan
CAS:76588-87-9
Purity:HPLC>=94% Package:5mg Remarks:B29935
|
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
| Products Intro: |
Product Name:Yadanzigan
CAS:76588-87-9
Purity:99.98% Package:1mg/RMB 1290;5mg/RMB 3280;10mg/RMB 4690
|
| Company Name: |
Wuhan Zhongzhicheng Biotechnology Co., Ltd.
|
| Tel: |
13628624121 13628604890 |
| Email: |
1205052329@qq.com |
| Products Intro: |
Product Name:Yadanzigan
CAS:76588-87-9
Purity:98% HPLC Package:1mg;5mg;10mg;20mg;50mg;100mg;
|
|
| | Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Basic information |
| Product Name: | Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- | | Synonyms: | Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)-;Yadanzigan | | CAS: | 76588-87-9 | | MF: | C26H38O14 | | MW: | 574.57 | | EINECS: | | | Product Categories: | | | Mol File: | 76588-87-9.mol |  |
| | Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Chemical Properties |
| Melting point | 243-245 °C | | Boiling point | 835.5±65.0 °C(Predicted) | | density | 1.68±0.1 g/cm3(Predicted) | | pka | 11.47±0.70(Predicted) |
| | Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Usage And Synthesis |
| Uses | Yadanzigan (YDZG) is an anti-inflammatory agent and a NLRP3 inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice[1]. | | in vivo | Yadanzigan (5 mg/kg, 10 mg/kg; i.v.; dose for 3 times) prevents LPS-induced acute lung injury in mouse model[1]. | Animal Model: | Male BABL/C mice (18-22 g)[1] | | Dosage: | 5 mg/kg, 10 mg/kg | | Administration: | Intravenous injection; dose at 2 h prior to and 6 h, 12 h after LPS induction
| | Result: | Reduced LPS-induced infiltration of inflammatory cells and cytokine levels, such as TNF-α and IL-6. Inhibited NLRP3 inflammasome activation in lung tissue.
Resulted significantly greater survival rate. |
| | IC 50 | NLRP3 inflammasome | | References | [1] Cui Y, et al. Yadanzigan, a quassinoid glucoside, attenuates NLRP3 inflammasome activation to prevent LPS-induced acute lung injury. Authorea Preprints, 2020. |
| | Picras-3-en-16-one, 13,20-epoxy-2-(β-D-glucopyranosyloxy)-1,11,12,14,15-pentahydroxy-, (1β,2α,11β,12α,15β)- Preparation Products And Raw materials |
|